metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Fosfomicina: un antibiótico infravalorado en infecciones urinarias por Escheric...
Información de la revista
Vol. 19. Núm. 10.
Páginas 462-466 (diciembre 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 10.
Páginas 462-466 (diciembre 2001)
Acceso a texto completo
Fosfomicina: un antibiótico infravalorado en infecciones urinarias por Escherichia coli
Visitas
120630
Margarita Garaua,1
Autor para correspondencia
apalacioh@hdoc.insalud.es

Correspondencia: Dra M. Garau Colom.Servicio de Microbiología.Hospital Universitario 12 de Octubre.Carretera de Andalucía, km 5,4.28041 Madrid
, Adela Latorrea
a Servicio de Microbiología. Hospital Universitario 12 de Octubre
Mercedes Alonso-Sanzb
b Laboratorio de Microbiología. Centro de Especialidades Periféricas (CEP) Carabanchel, Área 11. Madrid
Este artículo ha recibido
Información del artículo
Fundamentos

Evaluar los patrones de sensibilidad de los aislamientos de Escherichia coli obtenidos a partir de muestras de orina de enfermos con infección del tracto urinario inferior adquirida en la comunidad, resaltando el papel de la fosfomicina trometamol en el tratamiento de la misma

Métodos

Se revisó de manera retrospectiva la sensibilidad de 16.227 aislamientos de E. coli, procedentes de urocultivos realizados en el Laboratorio de Microbiología del Área 11 de Madrid entre los años 1997-2000, a ampicilina, amoxicilina-clavulánico, cefalotina, cefuroxima, trimetoprim-sulfametoxazol, fosfomicina trometamol, nitrofurantoína y ciprofloxacino. Se determinó la sensibilidad por el sistema de microdilución automático Vitek (bioMèrieux, France)

Resultados

E. coli representó el 80,1% del total de uropatógenos aislados. La sensibilidad a ampicilina, amoxicilina-clavulánico, cefalotina, cefuroxima, trimetoprim–sulfametoxazol, nitrofurantoína y ciprofloxacino fue del 42,25%,81,5%,58,75%, 87,5%,70%,94,75% y 84,75%, respectivamente. Fosfomicina trometamol fue el antibiótico que presentó mayor actividad frente a E. coli, siendo el 95,5% de los aislamientos sensibles

Conclusiones

Fosfomicina trometamol (dosis única) es una buena alternativa que debe considerarse en el tratamiento de infecciones del tracto urinario inferior no complicadas

Palabras clave:
Escherichia coli
infección del tractourinario
sensibilidad antibiótica
fosfomicina trometamol
Objectives

To evaluate the sensitivity patterns of Escherichia coli isolates obtained from urine specimens from patients with community-acquired urinary tract infections, with a special emphasis on fosfomycin trometamol for the treatment of UTI

Methods

Retrospective analysis of the sensitivity pattern of 16,227 E. coli isolates recovered from urine cultures performed at the Microbiology Laboratory of Madrid Area 11 from 1997 to 2000. The antimicrobial agents tested included ampicillin, amoxycillin-clavulanate, cephalotin, cefuroxime, trimethoprim-sulphamethoxazol, fosfomycin trometamol, nitrofurantoin, and ciprofloxacin. Antibiotic sensitivity testing was performed with the Vitek automatic microdilution system (bioMèrieux, France)

Results

E. coli represented 80.1% of all uropathogens recovered. The percentages of sensitive strains to ampicillin, amoxycillin-clavulanate, cephalotin, cefuroxime, trimethoprim-sulphamethoxazol, nitrofurantoin, and ciprofloxacin were 42.25%, 81.5%, 58.75%, 87.5%, 70%, 94.75%, and 84.75%, respectively. Fosfomycin trometamol was the antibiotic with the highest activity against E. coli, with 95.5% of sensitive isolates

Conclusions

Fosfomycin trometamol (single dose) is a good alternative that should be considered for the treatment of non-complicated lower urinary tract infections

Key words:
Escherichia coli
urinary tract infection
antibiotic sensitivity
fosfomycin trometamol
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.S. Patel, J.A. Balfour, H.M. Bryson.
Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.
Drugs, 53 (1997), pp. 637-656
[2.]
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Villanova, Pa, 2000
[3.]
Comité de l´Antibiogramme de la Société Française de Microbiologie. Communiqué 1999.
Pathologie Biologie, 46 (1999), pp. I-XVI
[4.]
R.R. Bailey.
Review of published studies on single dose therpay of urinary tract infections.
Infection, 18 (1990), pp. 53-56
[5.]
F. Caron, G. Humbert.
Short-term treatment of urinary tract infections: the french concept.
Infection, 20 (1992), pp. 286-290
[6.]
T. Bergan.
Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.
Infection, 18 (1990), pp. 65-69
[7.]
D. Greenwood, R. Edwards, J. Brown, P. Ridout.
The comparative activity of fosfomycin trometamol against organisms isolated from infected urines.
Infection, 20 (1992), pp. 302-304
[8.]
A.L. Barry, P.C. Fuchs.
In vitro susceptibility testing procedures for fosfomycin tromethamine.
Antimicrob Agents Chemother, 35 (1991), pp. 1235-1238
[9.]
G.C. Schito, C. Chezzi, G. Nicoletti, M. Moreddu, M.C. Arcangeletti, S. Stefani, et al.
Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an italian multicenter survey.
Infection, 20 (1992), pp. 291-295
[10.]
J.I. Alós, D. Balas, J.L. Gómez-Garcés.
Grupo de Estudio de Infección en Atención Primaria. Prevalencia de susceptibilidad a quinolonas y otros antibióticos en microorganismos aislados en bacteriurias extrahospitalarias de Madrid en 1995.
Rev Clin Esp, 197 (1997), pp. 167-171
[11.]
F.W. Goldstein.
Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France.
Eur J Clin Microbiol Infect Dis, 19 (2000), pp. 112-117
[12.]
JBJ Boerema, FTC. Willems.
Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary tract infections in general practice.
Infection, 18 (1990), pp. 80-88
[13.]
G.E. Stein.
Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.
Clin Therap, (1999), pp. 1864-1872
[14.]
F.P. Selvaggi, P. Ditonno, A. Traficante, M. Battaglia, V. Di Lorenzo.
Fosfomycin trometamol (Monuril) versus norfloxacin in single dose for adult female uncomplicated UTIs.
Chemotherapy, 36 (1990), pp. 31-33
[15.]
R. Harvard Davis, T.C. O´Dowd, W. Holmes, J. Smail, R.C.B. Slack.
A compa-rative double-blind randomized study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice.
Chemotherapy, 36 (1990), pp. 34-36
[16.]
H.C. Neu, T.C. O´Dowd, W. Holmes, J. Smail, R.C.B. Slack.
Fofomycin trometamol versus amoxycillin-single-dose: multicenter study of urinary tract infections.
Chemotherapy, 36 (1990), pp. 19-23
[17.]
K.G. Naber, U. Thyroff-Friesinger.
Fosfomycin trometamol versus ofloxacin/ cotrimoxazole as single-dose therapy of acute uncomplicated urinary tract infection in females: A multicentre study.
Infection, 18 (1990), pp. 70-76
[18.]
P. Crocchiolo.
Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice.
Chemotherapy, 36 (1990), pp. 37-40
[19.]
J. Cooper, A.L. Raeburn, W. Brumfitt, J.M.T. Hamilton-Miller.
General practitioner study: fosfomycin trometamol versus amoxycillin clavulanate in acute urinary tract infections.
Chemotherapy, 36 (1990), pp. 24-26
[20.]
J. Reynaert, D. Van Eyck, J. Vandepitte.
Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice.
Infection, 18 (1990), pp. 77-79
[21.]
G. Elhanan, H. Tabenkin, R. Yahalom, R. Raz.
Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women.
Antimicrob Agents Chemother, 38 (1994), pp. 2612-2614
[22.]
M.A. Minassian, D.A. Lewis, D. Chattopadhyay, B. Bovill, G.J. Duckworth, J.D. Williams.
A comparison between single-dose fosfomycin trometamol (Monuril ®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.
Int J Antimicrob Agents, 10 (1998), pp. 39-47
[23.]
N. Principi, R. Corda, D. Bassetti, L.A. Varese, L. Peratoner.
Fosfomycin trometamol versus netilmicin in children´s lower urinary tract infections.
Chemotherapy, 36 (1990), pp. 41-45
[24.]
S.H. Zinner.
Management of urinary tract infections in pregnancy: a review with comments on single dose therapy.
Infection, 20 (1992), pp. 280-285
[25.]
S. Zinner.
Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy.
Chemotherapy, 36 (1990), pp. 50-52
[26.]
H. Thoumsin, M. Aghayan, R. Lambotte.
Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: prelimianry results.
Infection, 18 (1990), pp. 94-97
[27.]
G. Ferraro, G. Ambrosi, L. Bucci, R. Palmieri, G. Palmieri.
Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly.
Chemotherapy, 36 (1990), pp. 46-49
[28.]
A.P. MacGowan, R.A. Bailey, W. Egner, D.M. Picken, D.S. Reeves.
An open study of the efficacy and safety of single dose fosfomycin trometamol in treatment of hospitalised patients with urinary tract infection (pilot study).
Infection, 18 (1990), pp. 107-108
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos